Bausch Health Companies (BHC) Research & Development (2009 - 2026)

Bausch Health Companies has reported Research & Development for 18 years, with the latest figure at $173.0 million in Q2 2026.

• Quarterly Research & Development rose 8.81% year-over-year to $173.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $663.0 million (up 8.51% YoY) and the FY2025 annual result came in at $629.0 million, up 2.11% from the prior year.
• Research & Development climbed to $173.0 million in Q2 2026 per BHC's latest filing, from $163.0 million in the prior quarter.
• Over five years, Research & Development peaked at $173.0 million in Q2 2026 and troughed at $127.0 million in Q1 2022.
• A 5-year average of $150.8 million and a median of $152.5 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development advanced 22.83% in 2023, then decreased 5.3% in 2025.
• Over 5 years, Research & Development stood at $142.0 million in 2022, then climbed by 7.04% to $152.0 million in 2023, then increased by 7.24% to $163.0 million in 2024, then retreated by 1.23% to $161.0 million in 2025, then rose by 7.45% to $173.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $173.0 million, $163.0 million, and $161.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.